GeneQuantum Healthcare
June 16, 2025
Company Presentation
Oncology
GeneQuantum (GQ) has developed a strong pipeline of next-gen of ADCs with wider therapeutic window & higher affordability with its proprietary One-Enzyme-One-Reaction bioconjugation technology (DAR2/4/6/8, super stable both in circulation and in storage in liquid form, ADCC depletion w/o Fc engineering, ADCs manufactured in mAb facility, dual payload pADCs, RDCs, and AOCs, etc.) with 5 clinical programs including 1 currently in registration trial in China.
Strategic Collaborations:
Biohaven: out licensed the global right of GQ1011 (anti-FGFR3 ADC )
Biohaven: long term strategic collaboration to develop ADCs on multi-targets
AimedBio: long term strategic collaboration to develop ADCs on multi-targets
Pyramid: out licensed the ex-China right of GQ1010 (anti-TROP2 ADC)
2024 BD Milestone: executed 4 out-licensing deals in 2024 with total US$13B, the most # of deals done by a Chinese ADC in 2024
.jpg)
Company HQ City:
Suzhou
Company HQ State:
Jiangsu Province
Company HQ Country:
China
Year Founded:
2013
Lead Product in Development:
GQ1005 (HER2 ADC)
CEO
Gang Qin
Development Phase of Lead Product
Phase III
Number of Unlicensed Products Looking for Licensing
10
What is your next catalyst (value inflection) update?
Sep. 2025
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}